. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Gynecol Oncol. 2019 Apr 13;154(1):150–155. doi: 10.1016/j.ygyno.2019.04.006

Table 5.

Predictive statistics for ROMA and the combination of CA-125, HE4, YKL-40, transthyretin, ApoA1, Beta 2 microglobulin, transferrin, LPA and menopausal status (8 Marker Assay) for EOC versus benign disease at a specificity level of ~75%.

	ROMA (95% CI)	8 Marker Assay (95% CI)

Sensitivity	90.0% (79.5–96.2%)	94.0% (83.5–98.7%)
Specificity	76.7% (67.3–84.5%)	76.3% (66.4–84.5%)
PPV	69.2% (57.8–79.2%)	68.1% (55.8–78.8%)
NPV	92.9% (85.3–97.4%)	95.9% (88.6–99.2%)
Accuracy	81.6% (74.8–87.2%)	82.5% (75.3–88.4%)